78 related articles for article (PubMed ID: 3112919)
1. Some chemical properties of tissue plasminogen activator purified from paranasal mucous membrane.
Kosugi T; Nakamura M; Tsukayama T; Haraguchi S; Noda Y
Rhinology; 1987 Jun; 25(2):129-32. PubMed ID: 3112919
[TBL] [Abstract][Full Text] [Related]
2. Fibrin binding, fibrinolytic and fibrinogenolytic activity of plasminogen activator derived from the paranasal mucous membrane of humans.
Yamashiro Y; Nakamura M; Huang GW; Kosugi T
Laryngoscope; 1993 Feb; 103(2):197-202. PubMed ID: 8426513
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic activity in medium from tissue culture of paranasal mucous membrane.
Kosugi T; Nakamura M; Koja S; Haraguchi S; Noda Y
Rhinology; 1987 Sep; 25(3):195-8. PubMed ID: 3118447
[TBL] [Abstract][Full Text] [Related]
4. Purification and characterization of tissue-type plasminogen activator in maxillary mucosa with chronic inflammation.
Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
Thromb Haemost; 1985 Aug; 54(2):485-9. PubMed ID: 3936218
[TBL] [Abstract][Full Text] [Related]
5. Studies on proactivator from the paranasal mucous membrane in chronic sinusitis.
Kosugi T; Takagi I; Kinjo K; Ura M; Okamoto K; Sueno K; Mihara H
Rhinology; 1983 Dec; 21(4):309-13. PubMed ID: 6686718
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of tissue plasminogen activator from paranasal mucous membrane in chronic sinusitis.
Kosugi T; Matsuo O; Mihara H; Hirano K; Hamaya M
Ann Otol Rhinol Laryngol; 1982; 91(1 Pt 1):101-5. PubMed ID: 7041770
[TBL] [Abstract][Full Text] [Related]
7. Presence of urokinase-type plasminogen activator (u-PA) in tissue extracts of antrochoanal polyp.
Yamashiro Y; Nakamura M; Huang GW; Kosugi T
Laryngoscope; 1992 Sep; 102(9):1049-52. PubMed ID: 1518351
[TBL] [Abstract][Full Text] [Related]
8. The role of fibrinolytic enzymes in inflammation and paranasal mucous membrane.
Kosugi T; Kinjo K; Takagi I; Sueno K; Noda Y; Mihara M
Rhinology; 1984 Jun; 22(2):119-23. PubMed ID: 6540472
[TBL] [Abstract][Full Text] [Related]
9. Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site.
Dodd I; Nunn B; Robinson JH
Thromb Haemost; 1988 Jun; 59(3):523-8. PubMed ID: 3142086
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activators in tissue extract of aural cholesteatoma.
Nakamura M; Yamashiro Y; Nakahodo K; Sunagawa M; Huang GW; Kosugi T; Morimitsu T
Laryngoscope; 1995 Mar; 105(3 Pt 1):305-10. PubMed ID: 7877421
[TBL] [Abstract][Full Text] [Related]
11. Characterization of plasminogen activator produced by an established cell line from human ovary.
Matsuo C; Fukao H; Matsuo O
J Cell Physiol; 1988 Feb; 134(2):253-60. PubMed ID: 3126195
[TBL] [Abstract][Full Text] [Related]
12. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
13. Differences in physicochemical properties between tissue plasminogen activators from human paranasal mucous membrane and pig heart.
Kosugi T; Takagi I; Matsuo O; Mihara H; Morimitsu T; Hirano K; Hamaya M
Auris Nasus Larynx; 1981; 8(2):77-86. PubMed ID: 7199907
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators in human nasal polyps and mucosa.
Larsen K; de Maat MP; Jespersen J
Rhinology; 1997 Dec; 35(4):175-7. PubMed ID: 9532638
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator and plasminogen activator inhibitor antigen in tissue extracts of paranasal sinus mucous membranes affected by chronic sinusitis and antrochoanal polyps.
Sunagawa M; Kinjoh K; Nakamura M; Kosugi T
Eur Arch Otorhinolaryngol; 1999; 256(5):237-41. PubMed ID: 10392298
[TBL] [Abstract][Full Text] [Related]
16. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
17. Rational design of peptide ligand for affinity chromatography of tissue-type plasminogen activator by the combination of docking and molecular dynamics simulations.
Liu FF; Dong XY; Wang T; Sun Y
J Chromatogr A; 2007 Dec; 1175(2):249-58. PubMed ID: 17996243
[TBL] [Abstract][Full Text] [Related]
18. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators.
Korner G; Bjornsson TD; Vlodavsky I
J Cell Physiol; 1993 Mar; 154(3):456-65. PubMed ID: 8436596
[TBL] [Abstract][Full Text] [Related]
19. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
Bijnens AP; Knockaert I; Cousin E; Kruithof EK; Declerck PJ
Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
[TBL] [Abstract][Full Text] [Related]
20. On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells.
Rijken DC; Emeis JJ; Gerwig GJ
Thromb Haemost; 1985 Dec; 54(4):788-91. PubMed ID: 3937276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
